← Back

By health

Byhealth Co., Ltd. and its subsidiaries provide dietary supplements in China, Hong Kong, Australia, and internationally. Its products include protein powder, collagen, bone health products such as glucosamine, chondroitin, and calcium tablets, probiotics, capsules, and multivitamins under brands including By-Health, Jianlidu, and LifeSpace. The company also engages in scenic area tourism management, real estate, trade and investment, food sales, trademark management, and OTC licensing and outsourced processing. Products are sold through retail terminals such as pharmacies, supermarkets, and maternity and baby stores, as well as distributors and e-commerce platforms including Tmall, JD.com, Vipshop, Douyin, and Kuaishou. Formerly Guangdong By-Health Biotechnology Co., Ltd., it changed its name to Byhealth Co., Ltd. in April 2012, was incorporated in 1995, and is based in Guangzhou, China.

Country
Price · split & dividend adjusted
News & notes moving 300146.CS
300146.CS▼5

By-Health's 2026 interim report shows net profit attributable to shareholders of 603 million yuan, down 18.11% year-on-year

By-Health has released its 2026 interim report, with net profit attributable to shareholders of 603 million yuan, a decline of 18.11% compared to the same period last year. The company's total operating revenue was 3.671 billion yuan, and net cash inflow from operating activities was 178 million yuan, down 72.21% year-on-year. The latest gross profit margin was 70.33%, and ROE was 5.55%, a decrease of 1.03 percentage points from the same period last year.
300146.CS · Capital · Negative Net profit down 18.11% YoY and operating cash flow down 72.21%
Read original ↗
Jiemian·56dRead more →
Artificial Intelligence3

By-Health Plans to Invest an Additional 70 Million Yuan in Moonshot AI Ltd

By-Health announced that it plans to invest an additional 70 million yuan of its own funds in Moonshot AI Ltd. After this investment, the company and its subsidiaries will have invested a total of approximately 175 million yuan in the target company. This additional investment constitutes a related-party transaction, which has been approved by the board of directors and does not require submission to the shareholders' meeting for review. The target company is in a high-valuation sector and is still in an early stage of development, with risks including technology research and development falling short of expectations and intense industry competition.
About megatrends
Artificial Intelligence › Closed / Frontier Labs Capital
300146.CS · Capital · Neutral By-Health plans to invest additional 70 million yuan in Moonshot AI, a related-party transaction, but the target is early-stage with high risks.
Read original ↗
300146.CS

By-Health invests 20 million yuan in venture capital fund

By-Health has invested 20 million yuan of its own funds in Gongqingcheng Lingyi Xingtu Venture Capital Partnership, holding a 48.78 percent stake as a limited partner. The fund primarily targets projects in emerging industries, with a partnership term of 20 years, aiming to leverage professional expertise to identify high-growth sectors and achieve capital appreciation.
300146.CS · Capital · Neutral By-Health invests 20 million yuan as a limited partner in a venture capital fund, aiming for capital appreciation; impact depends on fund performance.
Read original ↗
财中社·69dRead more →
Semiconductors

Liang Wenfeng's Fund Participates in ChangXin Technology IPO; His Personal Wealth Reaches 244 Billion Yuan

ChangXin Technology is about to list on the STAR Market. Ningbo Huanfang Quantitative Investment Management Partnership and Zhejiang Jiuzhang Asset Management, both founded by DeepSeek and Huanfang Quantitative founder Liang Wenfeng, appeared on the IPO subscription list, collectively deploying nearly 200 funds to submit bids. ChangXin Technology is issuing shares at 8.66 yuan per share, with an IPO valuation of approximately 579.2 billion yuan. In the strategic placement, 30 institutions received a total allocation of 14.437 billion yuan. Several listed companies participated in the placement, and the preliminary online subscription winning rate was 0.40995452 percent. Announcements by By-Health and Korrun indirectly disclosed DeepSeek's valuation at approximately 325 billion yuan and 350.9 billion yuan respectively, while the Bloomberg Billionaires Index shows Liang Wenfeng's net worth at 36 billion US dollars, equivalent to about 244 billion yuan, ranking 63rd on the global rich list. Brokerage research reports estimate ChangXin Technology's steady-state market capitalization after listing to be in the range of 1 trillion to 4 trillion yuan, with a profit potential of about 3,000 to 26,000 yuan per winning lot. The six insurance companies that invested early have an unrealized gain of approximately 18.3 billion yuan based on the issue price, and if the steady-state market capitalization reaches 3 trillion yuan, the unrealized gain could exceed 100 billion yuan.
About megatrends
Semiconductors › Memory — DRAM, NAND & HBM ▲Capital
宁波幻方量化投资管理合伙企业(High-Flyer) · Capital · Positive High-Flyer (founded by Liang Wenfeng) participated in ChangXin Technology IPO strategic placement, potentially benefiting from the listing.
DeepSeek · Capital · Positive DeepSeek's founder Liang Wenfeng's fund participated in ChangXin Technology IPO, and DeepSeek's valuation was indirectly disclosed at 325-350.9 billion yuan, reflecting positive capital market interest.
Jiuzhang Asset Management Co Ltd · Capital · Positive Jiuzhang Asset Management, founded by Liang Wenfeng, participated in ChangXin Technology IPO, indicating active capital deployment.
300146.CS · Capital · Neutral By-Health's announcement indirectly disclosed DeepSeek's valuation, but no direct impact on By-Health itself.
300577.CS · Capital · Neutral Korrun's announcement indirectly disclosed DeepSeek's valuation, but no direct impact on Korrun itself.
Read original ↗
每日经济新闻·80dRead more →